CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2013-06-24): Screen middle-aged adults for hepatitis C: panel

Clinical

Screen middle-aged adults for hepatitis C: panel

Last Updated: 2013-06-24 19:15:30 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Adults born between 1945 and 1965 should be screened once for hepatitis C, the U.S. Preventive Services Task Force (USPSTF) recommended today.

The statement from the government-backed panel is stronger than draft recommendations published in November, which advised doctors to "consider offering screening" to members of the Baby Boom generation (see Reuters Health story of Nov 26, 2012).

The final recommendations - which also call for screening people at high risk of hepatitis C, such as injection drug users - were published Monday in the Annals of Internal Medicine.

The "moderate" net benefit of screening was supported by studies showing that patients with hepatitis C who achieve a sustained viral response to therapy are at lower risk of liver cirrhosis, cancer and death.

"New evidence came out since the draft recommendation, which gave us greater confidence in the linkage between a sustained viral response and important outcomes," Dr. Albert Siu, co-vice chair of the task force, told Reuters Health.

The USPSTF also found that tools used to assess liver health and guide treatment are becoming safer, and that the harms of hepatitis C medication, including headaches and flu-like symptoms, are "small."

Hepatitis C is treated with a combination regimen of ribavirin and peginterferon alfa (also commonly known as Pegasys and Peg-Intron), to which newer drugs - known as boceprevir (Victrelis) and telaprevir (Incivek) - can be added.

Dr. Siu, from the Icahn School of Medicine at Mount Sinai in New York, said the rate of hepatitis C among people born in 1945 through 1965 is about 4%, compared to about 1% among other Americans.

That difference is likely due to "risky behavior that was engaged in during this time," he said.

Many people living with hepatitis C are not aware they have the condition, the task force said, and may go years without showing symptoms.

Stanford University's Jeremy Goldhaber-Fiebert, who worked on one of the studies that influenced the updated recommendation, told Reuters Health that screening middle-aged adults seems to be effective and cost-effective - but that there are other considerations as well.

"It's really important that when screening is rolled out, that we ensure that those people who screen positive have access to timely, high-quality treatment," he said.

SOURCE: http://bit.ly/11CpW6W

Ann Intern Med 2013.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.